Therapeutic targeting of receptor tyrosine kinases in lung cancer (Q36158717)

12 August 2017

title

Therapeutic targeting of receptor tyrosine kinases in lung cancer (English)

1 reference

12 August 2017

1 reference

3

Ravi Salgia

1 reference

12 August 2017

Nicholas W Choong

1

1 reference

12 August 2017

Patrick C Ma

series ordinal

2

1 reference

12 August 2017

publication date

1 June 2005

1 reference

Expert Opinion on Therapeutic Targets

12 August 2017

language of work or name

English

0 references

published in

1 reference

12 August 2017

volume

9

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

533-559

1 reference

publication type of scholarly work

12 August 2017

review article

1 reference

Multidisciplinary management of lung cancer

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Novel targets for lung cancer therapy: part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Dimerization of cell surface receptors in signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Signal transduction via the MAP kinases: proceed at your own RSK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Severe acute interstitial pneumonia and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Gene structure of the human MET proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

c-Met: structure, functions and potential for therapeutic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Scatter factor is a fibroblast-derived modulator of epithelial cell mobility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Molecular cloning and expression of human hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Evidence for the identity of human scatter factor and human hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Organization of the human hepatocyte growth factor-encoding gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Signalling by semaphorin receptors: cell guidance and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Scatter-factor and semaphorin receptors: cell signalling for invasive growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Essential role of Gab1 for signaling by the c-Met receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

The "Gab" in signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Molecular cloning of a new transforming gene from a chemically transformed human cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Mechanism of met oncogene activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Overexpression of the Met/HGF receptor in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

A novel germ line juxtamembrane Met mutation in human gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

The Sema domain of Met is necessary for receptor dimerization and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Vascular endothelial growth factor B, a novel growth factor for endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Vascular endothelial growth factor is essential for corpus luteum angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver--conditioned medium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Primary structure and functional expression of rat and human stem cell factor DNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Kit receptor dimerization is driven by bivalent binding of stem cell factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Kit expression in small cell carcinomas of the lung: effects of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

Strain-dependent epithelial defects in mice lacking the EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.3.533

21 January 2018

Identifiers

DOI

10.1517/14728222.9.3.533

1 reference

12 August 2017

1 reference